TORONTO, Oct. 16 /CNW/ - Alegro Health Corp. (TSX-V: AGO), a provider of
medical, surgical and disability management, and clinical trial administration
services, today announced that Dr. Martin Barkin has been appointed Chairman
of Alegro's Board of Directors.
Former chairperson Brenda Rasmussen, President and Chief Executive
Officer of Alegro Health Corp., will remain on the board of directors.
"The appointment of Dr. Barkin as the new Chairman of our Board of
Directors demonstrates our commitment to recruiting knowledgeable and
experienced professionals and our ability to attract high caliber individuals
to our team," said Ms. Rasmussen. "Dr. Barkin's extensive experience in both
the public health care sector with the Ontario Ministry of Health and the
private sector with DRAXIS Pharma provides unique insight into the business
model and growth opportunities of Alegro."
Dr. Barkin currently serves as a director for Allon Therapeutics, a TSX
listed biotechnology company and sits on the Advisory Board for Viventia
Biotech. Dr. Barkin is also a professor in the Faculty of Medicine at the
University of Toronto, in the Department of Surgery as well as the Department
of Health Administration. From 1993 to 2007 Dr. Barkin was the President and
CEO of DRAXIS Health Inc., as well as a Director of several TSX and NASDAQ
listed companies. Dr. Barkin served as the Deputy Minister of Health, Ontario,
from 1987 to 1991 and received the Queen Elizabeth II Silver Jubilee Award.
About Alegro Health Corp.
Alegro Health Corp. is a leading healthcare services provider capturing
high value opportunities by providing additional access to select quality
healthcare services. Through its divisions - Disability & Rehabilitation
Management; Surgical/Hospital Services, and Drug Trial Management - Alegro is
delivering additional resources to the Canadian public healthcare services and
addressing the growing demand for private and enhanced out-of-pocket
healthcare services. With superior knowledge of the healthcare industry,
extensive and trusted relationships with payers, physicians, and government
agencies, Alegro is pursuing a vertically integrated approach and an
aggressive acquisition strategy to achieve its growth objectives. Alegro is
listed on the TSX Venture Exchange under the symbol AGO. For further
information, please visit www.alegrohealth.com.
Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
This release was prepared by management of the Company who takes full
responsibility for its contents. The TSX Venture Exchange has not
reviewed and does not accept responsibility for the adequacy or accuracy
of this news release.
For further information:
For further information: Brenda Rasmussen, President and CEO, (416)
496-6166, xt. 328, email@example.com; Thien Ly, Investor Relations,
(416) 815-0700, xt. 251, firstname.lastname@example.org; Michael Moore, Investor
Relations, (416) 815-0700, xt. 241, email@example.com